Phase 4 Brain Cancer Trial, Recruiting NCT06072807 Sponsor: Weill Medical College of Cornell University Condition: Brain Cancer
Back to Brain Cancer

Phase 4 Brain Cancer Trial, Recruiting

NCT06072807
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have an active diagnosis of ER+ (estrogen receptor positive) breast cancer, confirmed by biopsy, and who have brain metastases (cancer that has spread to the brain) that are either new or have come back, confirmed by biopsy or suspected based on an MRI scan
  • People who are able to give their informed consent to take part in the trial
  • People who stopped taking certain hormone-blocking medications at least 8 weeks ago (ER modulators) or at least 28 weeks ago (ER down regulators), as guided by the manufacturer's instructions
  • People who are 18 years of age or older
  • People who have a good general level of physical functioning, rated 0 or 1 on a standard medical scale (confirm with trial site)
  • People whose life expectancy is estimated to be at least 6 months
  • People who are already planned to receive radiation treatment for their brain metastases

Who may not be able to join:

  • People who are pregnant
  • People who are unable to undergo standard of care treatment (confirm with trial site)
  • People who have an allergy to FES, which is the imaging agent used in this trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Jana Ivanidze, MD/PhD, Weill Medical College of Cornell University

Phone: 212-746-4587

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
27 December 2023
Est. completion
1 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Mean SUV; Maximum SUV; SUV Ratio; Target-to-Background Ratio; Influx (Ki); Distribution volume (Vt) for scan times

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov